Trial Profile

Study of immune deficiency patients treated with subcutaneous immunoglobulin (IgPro20, Hizentra) on weekly and biweekly schedules

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary)
Indications Immunodeficiency disorders
Focus Adverse reactions; Pharmacokinetics
Sponsors CSL Behring

Most Recent Events

24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
05 Mar 2018 Results (n=17) assessing PK data of SCIG infusions every 2 weeks (biweekly), were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
23 Feb 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com